HCV/HIV Coinfection- STUDY: MULTICENTER STUDY TO EVALUATE THE EFFICACY OF 48 WEEKS COMBINATION-THERAPY WITH PEGYLATED INTERFERON ALFA 2A (PEG-IFN ALFA 2A) AND DIFFERENT DOSES OF RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C AND HIV -COINFECTION

Trial Profile

HCV/HIV Coinfection- STUDY: MULTICENTER STUDY TO EVALUATE THE EFFICACY OF 48 WEEKS COMBINATION-THERAPY WITH PEGYLATED INTERFERON ALFA 2A (PEG-IFN ALFA 2A) AND DIFFERENT DOSES OF RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C AND HIV -COINFECTION

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2015

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms HIVCopeg
  • Most Recent Events

    • 26 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top